European Federation of Clinical Chemistry and Laboratory Medicine Strategic Conference 2026, held in Prague, Czech Republic, brought together laboratory professionals, clinicians, and industry representatives to discuss key developments shaping the future of laboratory medicine, including artificial intelligence, harmonization, and evolving clinical demands.

As a Silver Partner of the EFLM Strategic Conference 2026, Wondfo further strengthened its engagement with the global laboratory medicine community, contributing to discussions on current trends and practical diagnostic needs.
 

Engaging with Laboratory Professionals and Experts

During the conference, Wondfo engaged with laboratory professionals, clinicians, and industry representatives across Europe, exchanging insights on current developments and evolving clinical needs in laboratory medicine.

Discussions covered areas such as testing efficiency, decentralized diagnostics, and emerging applications in clinical practice, reflecting growing interest in practical and scalable diagnostic solutions.
 

Prof. Tomáš Zima, EFLM President (second from right)

Highlighted Diagnostic Solutions

At the exhibition, Wondfo presented a range of diagnostic solutions designed to support different clinical scenarios and testing environments.

Wondfo's Fully-automatic CLIA analyzer - SmarLumi™ FC-2100

SmarLumi™ FC-2100 is only 0.64㎡ footprint with 60 sample positions and 25 reagent positions. It is very efficient with a high throughput of 200T per hour, providing accurate results in a short time. Wondfo's chemiluminescence platform demonstrated its capability in delivering reliable and efficient laboratory-based testing, supporting clinical laboratories with stable performance and scalable workflows.

Finecare™ FIA Platform and Finger-Tip Testing

Wondfo's Finecare™ platform is widely applicable across multiple settings such as beside diagnostics, acute and critical care, in-hospital testing, and emergency first-aid scenarios.

A key feature is the support for finger-tip whole blood testing, enabling convenient and rapid testing without the need for venous blood collection. Representative applications include:
· HbA1c testing for diabetes management
· Vitamin D testing for nutritional assessment
· CRP quantitative testing for infection and inflammation monitoring

These solutions are designed to improve accessibility and efficiency in routine screening and chronic disease management.
 

Alignment with Industry Trends

The conference emphasized key themes such as artificial intelligence, data-driven diagnostics, and the evolving role of laboratory medicine in clinical decision-making.

Wondfo's strategic focus on AI and digitalization aligns with these industry directions. Through strategic investments in companies such as CellsVision Medical Technology, Shenzhen Shengqiang Technology, and Yizhun AI Technology, Wondfo is supporting the development of AI capabilities across imaging, pathology, and laboratory diagnostics.

At the application level, AI technologies are being explored to enhance diagnostic efficiency and support clinical decision-making. Internally, digital systems are being implemented across R&D, manufacturing, and commercial operations to improve overall efficiency.
 

Looking Ahead

Participation in EFLM Strategic Conference 2026 reflects Wondfo's ongoing commitment to staying closely connected with the global laboratory medicine community.

Moving forward, Wondfo will continue to focus on innovation, strengthen international collaboration, and support the development of diagnostic solutions that improve clinical efficiency and expand access to testing worldwide.